Back to Journals » Therapeutics and Clinical Risk Management » Volume 9

The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients

Authors Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y

Received 24 June 2013

Accepted for publication 16 July 2013

Published 2 September 2013 Volume 2013:9 Pages 355—360

DOI https://doi.org/10.2147/TCRM.S50407

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yalong Dang,1,2,* Yalin Mu,2,* Manli Zhao,2 Lin Li,3 Yaning Guo,4 Yu Zhu1,2

1Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 2Department of Ophthalmology and Visual Science, Yellow River Hospital of Henan University of Science and Technology, Sanmenxia City, Henan, People's Republic of China; 3Department of Ophthalmology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang City, Henan, People's Republic of China; 4Gu-Cheng Eye Hospital, Xi'an City, Shanxi, People's Republic of China

*These authors contributed equally to this work

Purpose: To evaluate the effect of Helicobacter pylori (H. pylori) eradication on the remission of acute idiopathic central serous chorioretinopathy (ICSCR).
Study design: A prospective, randomized, placebo-controlled study of 53 participants.
Main outcome measure: Twenty-seven acute ICSCR patients tested positive for H. pylori were given an eradication H. pylori therapy, and another 26 patients with the same diagnosis received matching placebo medication. All participants were tested for the following items: (1) disappearance rate of subretinal fluid (SRF); (2) best-corrected visual acuity (BCVA); and (3) central retinal sensitivity at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after treatment. The difference between the two groups was analyzed by PASW statistics version 18.0.
Results: At each follow-up, the disappearance rate of SRF in the active treatment group seemed slightly better than in the control group, but no statistically significant differences were observed (P > 0.05 at each follow-up). The BCVA between the two groups also did not demonstrate statistically significant differences (P > 0.05 at each follow-up). Unlike the BCVA and the disappearance rate of SRF, we compared the change in central retinal sensitivity at 12 weeks after treatment; a statistical difference was observed (P = 0.042).
Conclusion: Our findings suggested that H. pylori eradication does not improve BCVA and the disappearance rate of SRF, but it could improve the central retinal sensitivity in acute ICSCR patients. We recommend that chronic ICSCR patients and more sensitive methods for H. pylori diagnosis should be involved in evaluating the effect of H. pylori eradication.

Keywords: Helicobacter pylori, acute idiopathic central serous chorioretinopathy, best-corrected visual acuity, subretinal fluid, central retinal sensitivity


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Papaverine inhibits lipopolysaccharide-induced microglial activation by suppressing NF-κB signaling pathway

Dang Y, Mu Y, Wang K, Xu K, Yang J, Zhu Y, Luo B

Drug Design, Development and Therapy 2016, 10:851-859

Published Date: 26 February 2016

Lower cognitive function in patients with age-related macular degeneration: a meta-analysis

Zhou LX, Sun CL, Wei LJ, Gu ZM, Lv L, Dang Y

Clinical Interventions in Aging 2016, 11:215-223

Published Date: 24 February 2016

Diffuse anterior retinoblastoma: current concepts

Yang J, Dang Y, Zhu Y, Zhang C

OncoTargets and Therapy 2015, 8:1815-1821

Published Date: 22 July 2015

Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy

Dang Y, Sun X, Xu Y, Mu Y, Zhao M, Zhao J, Zhu Y, Zhang C

Therapeutics and Clinical Risk Management 2014, 10:37-43

Published Date: 9 January 2014

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010